Skip to main content
  •   Home
  •   Download
  •   Manual
  •   Contact

Natural Product (NP) Details

General Information of the NP (ID: NP6530)
Name
Farnesol
Synonyms
farnesol; trans,trans-Farnesol; 106-28-5; (E,E)-Farnesol; (2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-ol; trans-Farnesol; (2E,6E)-Farnesol; 4602-84-0; 2-trans,6-trans-Farnesol; All-trans-Farnesol; Farnesyl alcohol; 3,7,11-Trimethyl-2,6,10-dodecatrien-1-ol; FCI 119a; Inhibitor A2; (E)-farnesol; HSDB 445; 2,6-Di-trans-Farnesol; 2,6,10-dodecatrien-1-ol, 3,7,11-trimethyl-, (2E,6E)-; (2-trans,6-trans)-farnesol; 2E,6E-farnesol; Farnesol (mixture of isomers); UNII-X23PI60R17; 3,7,11-Trimethyl-2,6,10-dodecatrienol; 2,6,10-Dodecatrien-1-ol, 3,7,11-trimethyl-; Farnesol, mixture of isomers; Floral Green; CHEBI:16619; 3,7,11-trimethyldodeca-2,6,10-trien-1-ol; X23PI60R17; (2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrien-1-ol; trans,trans-3,7,11-Trimethyl-2,6,10-dodecatrien-1-ol; 2,6,10-Dodecatrien-1-ol, 3,7,11-trimethyl-, (E,E)-; ST072172; Farnesol 97+% FCC; MFCD00002918; (E,E)-3,7,11-Trimethyl-2,6,10-dodecatrien-1-ol; FEMA No. 2478; Trimethyl dodecatrienol; EINECS 225-004-1; NSC 60597; EPA Pesticide Chemical Code 128911; polyprenols; transfarnesol; Nikkosome; trans- farnesol; AI3-44561; .beta.-Farnesol; E,E-farnesol; all-trans farnesol; (E,E)farnesol; FOF; trans,trans farnesol; Farnesol (6CI); (E,E,)-farnesol; Farnesol, 95%; (2Z,6Z)-Farnesol; Farnesol (2E,6E); Farnesol, (E,E)-; Farnesol, trans, trans; 2E,6E-Farnesyl alcohol; Spectrum5_002027; trans,trans-alpha-farnesol; DSSTox_CID_12389; DSSTox_RID_78934; trans,trans-Farnesol, 96%; trans,trans-Farnesol, 97%; DSSTox_GSID_32389; SCHEMBL58068; 2-trans-S-6-trans-farnesol; BSPBio_002660; Farnesol, analytical standard; CHEMBL25308; SPECTRUM1501022; (e,e)-FARNESOL 97+%; DTXSID2040789; BDBM11021; CHEBI:26199; CHEBI:28600; HY-Y0248A; AMY33538; BCP22704; ZINC1532860; Tox21_302034; AC-422; BBL027412; CCG-38862; s4941; SBB012426; STL372743; AKOS004907430; LMPR0103010001; MB00132; NCGC00095654-01; NCGC00095654-02; NCGC00095654-03; NCGC00095654-04; NCGC00095654-05; NCGC00255293-01; trans,trans-Farnesol, analytical standard; AS-16107; LS-14447; S409; CAS-4602-84-0; CS-0031456; 06F285; C01126; Farnesol, mixture of isomers, analytical standard; A801411; Q420449; Q-201851; W-109985; BRD-K24656285-001-01-0; Farnesol, mixture of isomers, >=95%, stabilized, FG; (2E, 6E)-3,7,11-trimethyl2,6,10-dodecatrien-1-ol; (2E,6E)-3,7,11-trimethyl-1-dodeca-2,6,10-trienol; (E,E,)-3,7,11-Trimethyl-2,6,10-dodecatrien-1-ol; F1905-7040; (2E,6E)-3,7,11-trimethyl-dodeca-2,6,10-trien-1-ol; Farnesol mixture of isomers stabilized with alpha tocopherol; UNII-EB41QIU6JL component CRDAMVZIKSXKFV-YFVJMOTDSA-N; 2,6,10-Dodecatrien-1-ol, 3,7,11-trimethyl- (8CI,9CI); A2865747-EC66-4B9C-A593-0A066A438904; (2-trans,6-trans)-3,7,11-trimethyldodeca-2,6,10-trien-1-ol
    Click to Show/Hide
Species Origin Mosla chinensis ...     Click to Show/Hide
Mosla chinensis
Kingdom: Viridiplantae
Phylum: Streptophyta
Class: Magnoliopsida
Order: Lamiales
Family: Lamiaceae
Genus: Mosla
Species: Mosla chinensis
Disease Candidosis [ICD-11: 1F23] Investigative [1]
Structure
Click to Download Mol
2D MOL

3D MOL

    Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product
Formula
C15H26O
PubChem CID
445070
Canonical SMILES
CC(=CCCC(=CCCC(=CCO)C)C)C
InChI
1S/C15H26O/c1-13(2)7-5-8-14(3)9-6-10-15(4)11-12-16/h7,9,11,16H,5-6,8,10,12H2,1-4H3/b14-9+,15-11+
InChIKey
CRDAMVZIKSXKFV-YFVJMOTDSA-N
CAS Number
CAS 4602-84-0
ChEBI ID
CHEBI:16619
Herb ID
HBIN026385
SymMap ID
SMIT00022
TCMSP ID
MOL000252
TTD Drug ID
D0M0CF
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP
          Fluconazole      Fungal infection     Click to Show/Hide the Molecular Data of This Drug
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    Molecule(s)
                    Regulation
Up-regulation Expression FDFT1  Molecule Info 
Pathway MAP
                    In-vitro Model Candida albicans SC5314 Microorganism model Candida albicans
                    Experimental
                    Result(s)
FAR and FAR/FLC affected fitness of C. albicans biofilm and the ERG gene regulation.
          Micafungin + Caspofungin     Click to Show/Hide the Molecular Data of This Drug
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [3]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    In-vitro Model Candida parapsilosis isolates Microorganism model Candida parapsilosis
Candida parapsilosis ATCC 22019 Microorganism model Candida parapsilosis
                    Experimental
                    Result(s)
Caspofungin and micafungin in combination with farnesol showed synergistcant interaction against Candida parapsilosis biofilms.
          Ibandronate + Docetaxel     Click to Show/Hide the Molecular Data of This Drug
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [4]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    In-vitro Model LNCaP CVCL_0395 Prostate carcinoma Homo sapiens
PC-3 CVCL_0035 Prostate carcinoma Homo sapiens
                    Experimental
                    Result(s)
Ibandronate effectively inhibits growth of prostate cancer cell lines via inhibition of the farnesyl-IPP-synthase and exhibits synergistic effects with docetaxel.
Target and Pathway
Target(s) Monoamine oxidase B (MAO-B)  Molecule Info  [5]
BioCyc Superpathway of tryptophan utilization Click to Show/Hide
2 Tryptophan degradation via tryptamine
3 Dopamine degradation
4 Putrescine degradation III
5 Noradrenaline and adrenaline degradation
KEGG Pathway Glycine, serine and threonine metabolism Click to Show/Hide
2 Arginine and proline metabolism
3 Histidine metabolism
4 Tyrosine metabolism
5 Phenylalanine metabolism
6 Tryptophan metabolism
7 Drug metabolism - cytochrome P450
8 Metabolic pathways
9 Serotonergic synapse
10 Dopaminergic synapse
11 Cocaine addiction
12 Amphetamine addiction
13 Alcoholism
Panther Pathway Adrenaline and noradrenaline biosynthesis Click to Show/Hide
2 5-Hydroxytryptamine degredation
3 Dopamine receptor mediated signaling pathway
Pathway Interaction Database Alpha-synuclein signaling Click to Show/Hide
WikiPathways Tryptophan metabolism Click to Show/Hide
2 Dopamine metabolism
3 Phase 1 - Functionalization of compounds
References
Reference 1 In vitro and in vivo Effect of Exogenous Farnesol Exposure Against Candida auris. Front Microbiol. 2020 May 20;11:957.
Reference 2 The impact of farnesol in combination with fluconazole on Candida albicans biofilm: regulation of ERG20, ERG9, and ERG11 genes. Folia Microbiol (Praha). 2018 May;63(3):363-371.
Reference 3 Effect of caspofungin and micafungin in combination with farnesol against Candida parapsilosis biofilms. Int J Antimicrob Agents. 2016 Apr;47(4):304-10.
Reference 4 Differential effects of ibandronate, docetaxel and farnesol treatment alone and in combination on the growth of prostate cancer cell lines. Acta Oncol. 2011 Jan;50(1):127-33.
Reference 5 The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
Cite NPCDR
Visitor Map
Correspondence

X. N. Sun, Y. T. Zhang, Y. Zhou, X. C. Lian, L. L. Yan, T. Pan, T. Jin, H. Xie, Z. M. Liang, W. Q. Qiu, J. X. Wang, Z. R. Li, F. Zhu*, X. B. Sui*. NPCDR: natural product-based drug combination and its disease-specific molecular regulation. Nucleic Acids Research. 50(D1): 1324-1333 (2020). PMID: 34664659

Prof. Feng ZHU  (zhufeng@zju.edu.cn)

College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China


Prof. Xinbing SUI  (hzzju@hznu.edu.cn)

School of Pharmacy and Department of Medical Oncology, the Affiliated Hospital of Hangzhou Normal University, Hangzhou Normal University, Hangzhou, China